Last week’s hot topic on pulmonary fibrosis was Experimental Pulmonary Fibrosis Therapy, GR-MD-02, Granted U.S. Patent Allowance and was written by Carolina Henriques.
This article is focused on Galectin Therapeutics, Inc‘s, announcement that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02.
PF is a scarring of the lung tissue, which can seriously affect a patient’s breathing capability. In PF, scar tissue builds up in the walls of the air sacs in the lungs, eventually compromising oxygen levels into the blood. Low oxygen levels, in turn, contribute to shortness of breath, particularly when walking or exercising.